Veru reports fiscal 2023 second quarter financial results

Agreement reached with fda on confirmatory phase 3 clinical trial design for sabizabulin treatment of hospitalized covid-19 adult patients at high risk for acute respiratory distress syndrome (ards), including two planned interim efficacy analyses
VERU Ratings Summary
VERU Quant Ranking